Boston Trust Walden Corp Decreases Position in Zoetis Inc. $ZTS

Boston Trust Walden Corp decreased its stake in Zoetis Inc. (NYSE:ZTS) by 9.6% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 122,279 shares of the company’s stock after selling 12,923 shares during the period. Boston Trust Walden Corp’s holdings in Zoetis were worth $14,455,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Global Wealth Strategies & Associates acquired a new position in Zoetis in the fourth quarter valued at $25,000. Prosperity Bancshares Inc purchased a new position in Zoetis during the 4th quarter worth approximately $25,000. KERR FINANCIAL PLANNING Corp purchased a new position in Zoetis during the 3rd quarter worth approximately $31,000. Lodestone Wealth Management LLC acquired a new position in Zoetis during the fourth quarter worth approximately $30,000. Finally, Elyxium Wealth LLC acquired a new position in Zoetis during the fourth quarter worth approximately $32,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Paul Bisaro acquired 2,000 shares of Zoetis stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the purchase, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael B. Mccallister acquired 3,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the acquisition, the director owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased 11,650 shares of company stock worth $886,384 in the last 90 days. 0.22% of the stock is currently owned by corporate insiders.

Zoetis Stock Down 0.1%

Zoetis stock opened at $74.73 on Friday. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. Zoetis Inc. has a 1-year low of $71.47 and a 1-year high of $161.77. The company has a market cap of $31.33 billion, a PE ratio of 12.39, a price-to-earnings-growth ratio of 1.17 and a beta of 0.75. The stock’s 50 day moving average price is $84.04 and its 200 day moving average price is $109.40.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. During the same quarter in the previous year, the company posted $1.48 EPS. The company’s revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.16%.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Neutral Sentiment: Barclays reiterated its Hold rating on Zoetis, signaling the firm still sees limited near-term upside after the company’s recent earnings miss and softer-than-expected revenue growth. Barclays Sticks to Its Hold Rating for Zoetis (ZTS)
• Neutral Sentiment: Zoetis also drew attention for its dividend profile, with commentary focused on dividend quality as a potential support for income-oriented investors. Zoetis Inc (NYSE:ZTS) Dividend Quality Draws Focus
• Negative Sentiment: Multiple law firms issued reminders about an investor lawsuit deadline tied to alleged securities fraud, with claims centered on possible misstatements and omissions about product adoption. These notices can add overhang and keep sentiment weak around ZTS. ZTS IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Zoetis Inc. Investors…
• Negative Sentiment: Additional class-action announcements from other firms reinforced the same legal overhang, keeping attention on the July 27 lead-plaintiff deadline rather than on business fundamentals. Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action…

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. JPMorgan Chase & Co. cut their target price on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Morgan Stanley restated an “overweight” rating and issued a $115.00 price objective on shares of Zoetis in a research note on Friday, May 15th. Argus reiterated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Finally, Citigroup lowered their target price on Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Seven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Zoetis has a consensus rating of “Hold” and an average price target of $126.92.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.